Ultragenyx Pharmaceutical traded at $24.10 this Friday April 24th, decreasing $0.18 or 0.74 percent since the previous trading session. Looking back, over the last four weeks, Ultragenyx Pharmaceutical lost 21.41 percent. Over the last 12 months, its price fell by 36.73 percent. Looking ahead, we forecast Ultragenyx Pharmaceutical to be priced at 23.58 by the end of this quarter and at 22.10 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy and nucleic acid product candidates. Its three approved product candidates include Crysvita (burosumab), for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa), for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome and Dojolvi (triheptanoin), for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). Its clinical product candidates include DTX401, for the treatment of glycogen storage disease type Ia (GSDIa), DTX301, for the treatment of ornithine transcarbamylase (OTC), UX143, GTX-102, UX701 and UX053.